Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR
Drug design of protein kinase inhibitors is now greatly enabled by thousands of publicly available X-ray structures, extensive ligand binding data, and optimized scaffolds coming off patent. The extensive dat...
Journal of Cheminformatics 2017 9:43
Published on: 4 July 2017